Enlivex Therapeutics Ltd
Change company Symbol lookup
Select an option...
ENLV Enlivex Therapeutics Ltd
OSSIF OneSoft Solutions Inc
FAZE FaZe Holdings Inc
AYTU Aytu Biopharma Inc
WFC Wells Fargo & Co
XOM Exxon Mobil Corp
URBF Urban Barns Foods Inc
ETO Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund
FMS Fresenius Medical Care AG & Co KGaA
JNJ Johnson & Johnson
Go

Health Care : Biotechnology | Small Cap Blend
Based in Israel
Company profile

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Postmarket

Last Trade
Delayed
$4.20
-0.06 (-1.41%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$4.26
Day's Change
-0.20 (-4.48%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
4.40
Day's Low
4.22
Volume
(Light)
Volume:
6,475

10-day average volume:
18,935
6,475

Display:

Providers:

UpdateCancel
6 providers
October 03, 2022
September 13, 2022
Enlivex to Present at Upcoming Investor and Media Conferences

EQNX::TICKER_START (NASDAQ:ENLV), EQNX::TICKER_END Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will be presenting at the following...(Globe Newswire)

September 12, 2022
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

EQNX::TICKER_START (NASDAQ:ENLV), EQNX::TICKER_END -- Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers -- Combining cisplatin with Allocetra(TM) led to a...(Globe Newswire)

September 06, 2022
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra(TM) to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

EQNX::TICKER_START (NASDAQ:ENLV), EQNX::TICKER_END Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors...(Globe Newswire)

August 29, 2022
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

EQNX::TICKER_START (NASDAQ:ENLV), EQNX::TICKER_END Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors...(Globe Newswire)

August 24, 2022
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

EQNX::TICKER_START (NASDAQ:ENLV), EQNX::TICKER_END -- Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and Greece. In addition to these clearances, Enlivex plans to obtain clearances for these...(Globe Newswire)

August 22, 2022
Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today filed with the SEC its financial results and related management's discussion for the second quarter ended June 30, 2022. (Globe Newswire)

August 17, 2022
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra(TM) Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

-- Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra(TM) was combined with PD1 checkpoint inhibition in a murine...(Globe Newswire)

August 03, 2022
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra(TM)

EQNX::TICKER_START (NASDAQ:ENLV), EQNX::TICKER_END Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.